• Explore /
  • Poster
  • / Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma.

Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma.

Abstract Video & Slides Poster

Authors

Raphael Steiner

Raphael Eric Steiner

The University of Texas MD Anderson Cancer Center, Department of Lymphoma/Myeloma, Houston, TX

Raphael Eric Steiner , Paolo Strati , Christopher Flowers , Sattva Swarup Neelapu , Michael Richard Green , Loretta J. Nastoupil , Fredrick B. Hagemeister Jr., Lei Feng , Sairah Ahmed , Ranjit Nair , Luis Fayad , Hun Ju Lee , Maria Alma Rodriguez , Jason Westin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04745949

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS7589)

DOI

10.1200/JCO.2022.40.16_suppl.TPS7589

Abstract #

TPS7589

Poster Bd #

236a

Abstract Disclosures

Similar Posters

First Author: M. A. Rodriguez

First Author: Xiangdong Cheng

First Author: Jason Westin

Poster

2023 ASCO Annual Meeting

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

First Author: Carrie Ho